IM-MV 16-007_012
|
UMCG
|
Testing the safety and efficacy of KTE-C19 in patients with refractory or relapsed B-cell malignancies
|
08-04-2024
|
Vergunning verleend
|
IM-MV 23-014_000
|
Erasmus MC
|
Multicenter, Open-label, Phase 1 Study of Allo-RevCAR01-T-CD123 Consisting of Genetically Modified T Cells Carrying Reverse Chimeric Antigen Receptors (Allo-RevCAR01-T) in Combination with CD123 Target Module (R-TM123) for the Treatment of Patients with Selected Hematologic MalignanciesPositive for CD123
|
08-04-2024
|
Vergunning verleend
|
IM-MV 23-015_000
|
UMCG
|
Multicenter, Open-label, Phase 1 Study of Allo-RevCAR01-T-CD123 Consisting of Genetically Modified T Cells Carrying Reverse Chimeric Antigen Receptors (Allo-RevCAR01-T) in Combination with CD123 Target Module (R-TM123) for the Treatment of Patients with Selected Hematologic Malignancies Positive for CD123
|
08-04-2024
|
Vergunning verleend
|
IM-MV 23-017_000
|
Amsterdam UMC
|
Multicenter, Open-label, Phase 1 Study of Allo-RevCAR01-T-CD123 Consisting of Genetically Modified T Cells Carrying Reverse Chimeric Antigen Receptors (Allo-RevCAR01-T) in Combination with CD123 Target Module (R-TM123) for the Treatment of Patients with Selected Hematologic MalignanciesPositive for CD123
|
08-04-2024
|
Vergunning verleend
|
IM-MV 24-001_000
|
Amsterdam UMC
|
Local oncolytic adenovirus administration to sensitize the immune microenvironment of esophageal adenocarcinoma for chemoradiation
|
|
Ontwerpbesluit genomen
|